Foundation Medicine to Present Prostate Cancer Biomarker Study at ESMO 2026

PUBT · 5d ago
Foundation Medicine to Present Prostate Cancer Biomarker Study at ESMO 2026
  • Foundation Medicine will present 12 research abstracts at the ESMO Congress, October 23-27, 2026, in Madrid.
  • Two rapid oral presentations will examine liquid-biopsy findings relevant to prostate cancer treatment selection and prognosis.
  • Other research identifies circulating tumor DNA tumor fraction as a predictor of resistance to systemic therapy across solid tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210700BIZWIRE_USPR_____20261021_BW800190) on October 21, 2026, and is solely responsible for the information contained therein.